Up next

How Will the Pharma Industry Perform in 2024 & the Near Term?

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Getting the latest market analysis and data

Graham Lewis 
Vice President, Global Pharma Strategy 
IQVIA

What are the key growth indicators for the global bio/pharmaceutical market in 2024 and over the next several years, and how will the industry perform over this time?  That is the trillion-dollar question for the bio/pharma industry.

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing valuable market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharma market analysis, will provide the latest market data and trends.

COVID-19 vaccines and therapeutics had been a boon for the industry, but with lower growth for these products, how will the industry perform relative to pre-pandemic growth trends? Is the industry’s performance trending upward or not? The program will examine the growth prospects and factors influencing performance for: innovator and generic drugs; leading therapeutic sectors, both pipelines and commercial products; and developed and emerging markets.

Daniel Cohen 
Managing Director & Global Head of Pharma Outsourcing Investment Banking
Morgan Stanley

A CMDO/CMO financial outlook
The performance of the industry as a whole is a factor in determining the health of the market for pharmaceutical outsourcing, which is further influenced by other factors. The program will also feature a Wall Street view of the CDMO/CMO sector, with Daniel Cohen, Managing Director & Global Head of Pharma Outsourcing Investment Banking, Morgan Stanley, providing a financial overview of the CDMO/CMO sector: performance & investor valuations. He will provide an analysis of key mergers & acquisitions and other trends impacting sector performance.

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 18, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for pre-program networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM. 

Information on the program, including how to register, may be found here.

Recent Feature Articles

US, EU Detail Plan for Pharmaceutical Tariffs

By
The White House and European Commission have released further details on the recently agreed-to US-EU trade deal, including further details on tariffs on pharmaceuticals. What’s the bottom line for the pharma industry?

Big Pharma & US Manufacturing Investment

By
The White House released last week a list of major capital investments in the US for manufacturing, including from the pharmaceutical industry. A roundup of investments gaining attention and other moves thus far in 2025.

State of the State: AI in Procurement: Where Does It Stand?

By
The potential of AI to transform business functions, including procurement, is strong, but where does it actually stand? A recent analysis by the business and technology consulting firm, Gartner, provides a reality check for current and future adoption.

White House Takes Next Steps To Onshore Mfg to US & Stockpiling APIs

By
FDA is seeking public comment through October 8 on how the US government can facilitate the onshoring of pharma manufacturing to the US. Also, President Donald Trump issues an Executive Order for stockpiling essential medicines in the US.